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A B S T R A C T
Status epilepticus (SE) is an acute and severe illness of the central nervous system, and prolonged SE can
lead to brain damage and even death. Ketamine is a noncompetitive antagonist of glutamatergic N-
methyl-D-aspartate (NMDA) receptors. During prolonged seizures, the numbers and activities of GABA
receptors gradually decrease; thus, the commonly used ﬁrst-line and second-line antiepileptic drugs
gradually fail. Simultaneously, the numbers and activities of glutamatergic NMDA receptors increase,
often causing refractory status epilepticus (RSE) and thus providing the possibility of the use of ketamine
to treat RSE. To improve the prognosis of SE, we present a narrative review of ketamine for the treatment
of RSE in the extant literature. We draw the conclusion that ketamine appears to be effective and
relatively safe for the control of multidrug-resistant RSE in children and adults.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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Refractory status epilepticus (RSE) refers to status epilepticus
(SE) that cannot be resolved in terms of clinical manifestations or
epileptiform discharges following the rational administration of
anticonvulsants including a benzodiazepine [1]. Super-refractory
status epilepticus (super-RSE) refers to drug-resistant status
epilepticus that persists or recurs following the continuous
administration of intravenous anesthetics for more than 24 h
[2], and the primary etiologies of super-RSE are brain insults, such
as intracranial infection, brain trauma or stroke [2,3]. SE is an acute
and severe illness of the central nervous system. When the seizure
duration exceeds 30 min, the mortality rate is 19% [4]. Among RSE
patients, the mortality rate is as high as 23–61% [5], and
approximately 90% of RSE survivors ultimately relapse [4,6,7]. Ke-
tamine could play an important role in the treatment of RSE by
altering glutamate metabolism, particularly in patients who
exhibit a poor response to benzodiazepines.
2. Background
Ketamine was developed by the Parke-Davis (USA) pharma-
ceutical company in 1962. Three years later, McCarthy et al. [8]
found the ﬁrst evidence that ketamine exerts an anticonvulsant
effect in epilepsy animal models that were electrically or* Corresponding author. Tel.: +86 136 2835 9876; fax: +86 023 8901 2878.
E-mail address: xfyp@163.com (X. Wang).
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1059-1311/ 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights rechemically created. These results were soon conﬁrmed in patients
[9], raising the possibility of treating SE using ketamine, although
this possibility was soon questioned. The experiments by Kayama
and Iwama [10] using cat models revealed that ketamine could
induce epileptic changes, based on EEG recordings. However, a
similar study of human volunteers conducted by Corssen et al. [11]
rejected this conclusion. These authors found that ketamine did
not cause epileptiform discharges in epilepsy patients or in normal
subjects and that no evidence was available to support the notion
that ketamine could induce or exacerbate convulsions, in contrast
with the conclusions of Kayama [12,13].
In recent years, many researchers have reported that, during
prolonged seizures, the number of activated GABA-A receptors on
the postsynaptic membrane gradually decreases, whereas the
number of inactive GABA-A receptors increases [14,15]. These
changes cause a signiﬁcant reduction in the efﬁcacy of antiepileptic
drugs (AEDs) that target the GABAergic system, such as diazepam,
clonazepam, valproic acid, midazolam, propofol, and phenobarbi-
tal. Increased doses of AEDs might restore their efﬁcacy, but the
side effects of AEDs on cardiopulmonary function are simulta-
neously signiﬁcantly increased, thus limiting the clinical applica-
tions of such increased doses. However, a study by Dingledine et al.
[16] reported that the number and activities of glutamate-sensitive
N-methyl-D-aspartate (NMDA) receptors signiﬁcantly increased
when the activity of GABA receptors decreased. Subsequently, this
process induced continuously ampliﬁed neuronal hyperexcitabili-
ty, leading to the development of RSE. Ketamine is a noncompeti-
tive NMDA receptor antagonist [16] that might play a role in
treating SE by blocking NMDA receptor-mediated glutamatergicserved.
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mediated NMDA receptor-induced neurotoxicity, ketamine also
exerts neuroprotection [19–21]. Therefore, ketamine has been
proposed as a new therapeutic agent for the treatment of SE [22–24].
3. Ketamine for the treatment of RSE
3.1. Clinical practice
Gaspard et al. [25] retrospectively analyzed the results of
intravenous ketamine treatment of RSE. This study included 58 RSE
patients treated with ketamine intravenously from 1999 to 2012,
among whom 46 patients were adults, and 12 patients were
children. These patients experienced a total of 60 episodes of RSE.
The results indicated that, among the 57% (34/60) of cases in which
the seizures ultimately resolved, approximately 32% (19/60) of the
seizures were halted due to the effects of ketamine, and
approximately 13% (8/60) of the cases of RSE were controlled
during ketamine use. Similarly, a prospective study by Rosati et al.
[26] also demonstrated that ketamine was relatively effective and
safe for the treatment of RSE. This study included 9 RSE children
who received intravenous ketamine between 2009 and 2011. In 8
patients, seizures had persisted for more than 1 day prior toTable 1
Demographics and clinical data of ketamine treatment in RSE.
Year Number
of
patients
Age (Y)/sex History of
epilepsy
Study type Etiology of RSE 
2014 1 Newborn
F
No Case report Brain malformation 
2013 58 24 (0.6–74)
Unknown
Yes (9);
unknown
(49)
Retrospective
study
Unknown (34); acut
symptomatic (20);
remote symptomatic
2013 11 52 (22–82)
F (4); M (7)
Yes (6);
no (5)
Retrospective
study
Low AED levels (3);
CNS infection (2);
systemic infection (3
sepsis (2); metabolic
disturbance (1)
2013 2 66; 57
F (1); M (1)
No Case report Elective aneurysm
clipping
2013 1 27
F
No Case report Viral encephalitis 
2012 9 5.2 (1.3–10.4)
F (5); M (4)
Yes (7);
no (2)
Prospective
study
Unknown (5);
malformative (2);
Rett syndrome (1);
MELAS (1)
2012 1 60
M
Yes Case report Unknown 
2011 1 76
F
Yes Case report Systemic infection;
low AED levels
2010 1 26
M
No Case report Unknown 
2008 1 22
F
Yes Case report Unknown 
2005 1 15
M
No Case report Undeﬁned, maybe
encephalitis
2003 1 44
M
Yes Case report Neurosyphilis 
2003 5 4 (4–7)
F (3); M (2)
Yes (5) Prospective study Epilepsy syndrome 
1998 1 13
F
No Case report Unknown 
1996 1 Unknown
M
Yes Retrospective
study
Cortical dysplasia 
AED: antiepileptic drug; CBZ: carbamazepine; CLB: clobazam; CNS: central nervous syste
focal convulsive status epilepticus; GCSE: generalized convulsive status epilepticus; GT
ketamine; LCM: lacosamide; LEV: levetiracetam; LTG: lamotrigine; LZP: lorazepam; M: m
and stroke-like episodes; NCSE: nonconvulsivestatusepilepticus; NZP: nitrazepam; PB:
RSE: refractory status epilepticus; RUF: ruﬁnamide; SE: status epilepticus; SG: secondar
years.ketamine selection. Finally, 6 patients who experienced RSE
resolution were thought to be associated with ketamine adminis-
tration, 2 patients were cured surgically, and no serious adverse
reactions were recorded in all of the patients. In 2003, Mewasingh
et al. [27] reported 6 cases of the use of oral ketamine to treat
children (4–7 years old) with nonconvulsive RSE (NCSE), including
Lennox–Gastaut syndrome, pseudo-Lennox syndrome, progressive
myoclonic epilepsy and myoclonic-astatic epilepsy. All of the
seizures remained prolonged despite the use of many antic-
onvulsants, and the median duration of these seizures was 4.4
weeks (range 2–10 weeks). Thus, these authors decided to use oral
ketamine to treat RSE; fortunately, all of the patients experienced
resolution within 24–48 h after the initiation of ketamine,
resulting in a clear reduction in epileptiform discharges on EEG
and improvement of the mental state of the patients. Although one
of the children experienced a relapse a few months later, the
continued use of ketamine remained effective, and no apparent
side effects were recorded during ketamine treatment. Herein, we
have summarized the available studies on ketamine for the
treatment of RSE, which are presented in Tables 1 and 2.
Collectively, these results indicate that ketamine is primarily
suitable for the treatment of RSE and super-RSE during prolonged
seizures, which is also supported by the conclusions of an animalSE type SE duration
prior to KET
Medications prior to KET References
GTCSE About 9d 5 (PB, MDZ, LEV, PHT, PRO) [29]
e
 (6)
GCSE (14);
NCSE (42);
FCSE (4)
9d (0–122d) 4.5 (1–10; unknown) [25]
);
GTCSE (6);
NCSE (5)
5d (1–11d) 3–8 (DZP, LZP, VPA, LEV,
TPM, CBZ, MDZ, PB, PHT,
GBP, PRO)
[30]
GTCSE (1);
NCSE (1)
18d and 4d 8 (PHT, MDZ, PRO, LEV, TPM,
PB, VPA, CLB)
5 (PHT, MDZ, PRO, VPA, LEV)
[31]
GTCSE Unknown 9 (LZP, LEV, MDZ, PHT, LCM,
PRO, TPM, PB, VPA)
[32]
GCSE (3);
focal (1);
focal  SG (5)
6d (5 h–26d) 5 (4–7; MDZ, TPM, CBZ, LEV,
THP, PRO, VPA, PHT, PB,
CZP, ETM,
NZP, RUF)
[26]
NCSE Within hours 4 (PHT, MDZ, PRO, LEV) [33]
NCSE 9d 10 (VPA, MDZ, LEV, PHT, PRO,
PB, LTG, CBZ, RGT, TPM)
[34]
GTCSE; NCSE 58d 8 (DZP, VPA, MDZ, LEV, PHT,
TPM, PRO, THP)
[35]
GCSE 13d 5 (LZP, PHT, THP, LEV, PRO) [36]
Unknown Unknown 4 (TPM, MDZ, PRO, PB) [37]
GTCSE; NCSE 5d 5 (LZP, PHT, LTG, VPA, PRO) [38]
NCSE (5) 4.4w (2–10w) 0–3 (LZP, MDZ, prednisolone) [27]
GTCSE 28d 8 (DZP, PHT, PB, LZP, LIDO,
VPA, PRO, MDZ)
[39]
NCSE Unknown Unknown [40]
m; CZP: clonazepam; d: days; DZP: diazepam; ETM: ethosuximide; F: female; FCSE:
CSE: generalized tonic-clonic status epilepticus; GBP: gabapentin; h: hours; KET:
ale; MDZ: midazolam; MELAS: mitochondrial encephalomyopathy, lactic acidosis,
 phenobarbital; PGB: pregabalin; PHT: phenytoin; PRO: propofol; RGT: retigabine;
y generalization; TPM: topiramate; THP: thiopental; VPA: valproate; w: weeks; Y:
Table 2
Ketamine treatment regime and efﬁcacy.
Year Number
of
patients
Administration Dosages Duration of
treatment
Onset time Time from
ketamine
initiation to
seizure cessation
Seizure
response
Outcome References
Bolus Infusion Oral
2014 1 Intravenous 2 bolus of 2mg/kg 10–24mg/kg/min 0 2d Unknown Unknown 15d without seizures SE reappeared and died [29]
2013 58 Intravenous Median 1.5mg/kg
(max 5mg/kg)
Median: 2.75mg/kg/h
(max 10mg/kg/h)
0 6h–27d Unknown Unknown 57% resolved Good outcome (5%);
mortality (45%)
[25]
2013 11 Intravenous 1–2mg/kg 1.3mg/kg/h
(0.45–2.1mg/kg/h)
0 9.8 (4–28d) Unknown 9.8 (4–28d) Completely resolved Home/rehabilitation (5);
need nursing (4); died (2)
[30]
2013 2 Intravenous 0 10–40mg/kg/min 0 3d and 12d Within several
hours; Within
30min
3d and 12d Completely resolved Rehabilitation (2) [31]
2013 1 Intravenous 1.5mg/kg 1.2–3.75mg/kg/h 0 12d Unknown Within 3d Completely resolved Rehabilitation [32]
2012 9 Intravenous 0.75mg/kg 0.6–3.3mg/kg/h 0 2d Immediately 12h Completely resolved Home [26]
2012 1 Intravenous 2 bolus of
2–3mg/kg
every 5min
36.5mg/kg/min
(10–60mg/kg/min)
0 6d (3–17d) Unknown Unknown Completely resolved in 6 Unknown [33]
2011 1 Intravenous
followed with
oral
1.5mg/kg 0.05–4mg/kg/h 1500–2000mg/d Unknown Unknown Unknown Completely resolved Home [34]
2010 1 Intravenous 0.5mg/kg 0.38–1.5mg/kg/h 0 7d 2d 5d Completely resolved Rehabilitation [35]
2008 1 Intravenous 0.5mg/kg 0.4–3.2mg/kg/h 0 14d Unknown 10d Completely resolved Comatose, tetraplegic [36]
2005 1 Intravenous Unknown Unknown Unknown Unknown Unknown Unknown Failure Died [37]
2003 1 Intravenous 2mg/kg 2–7.5mg/kg/h 0 5d Unknown 2d Completely resolved Diffused cerebral atrophy [38]
2003 5 Oral 0 0 1.5mg/kg/d in
two divided doses
5d Unknown Within 1–2d Completely resolved Good outcome (5) [27]
1998 1 Intravenous 2mg/kg 7.5mg/kg/h 0 14d 90s 2d Completely resolved Short-term memory and
cognitive deﬁcits
[39]
1996 1 Intravenous 0 100mg/h 0 Unknown Unknown Unknown Failure Controlled by sub-pial transection [40]
d: day(s); h: hour(s); kg: kilogram; min: minutes; s: seconds; SE: status epilepticus; mg: microgram.
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Y. Fang, X. Wang / Seizure 30 (2015) 14–20 17experiment [28]. These authors found that if ketamine treatment
was initiated after 15 min of SE, none of the animals exhibited
responses to ketamine (0/4); however, when ketamine was
initiated after 1 h of seizures, the successful termination rate
was 100% (4/4). Moreover, after a prolonged seizure duration, a
corresponding increase in the dose of ketamine was found to be
effective within a certain time period.
3.2. An evidence-based clinical study on the use of ketamine to treat
RSE
In 2014, Zeiler et al. [41] published a systematic review of
NMDA-receptor antagonists for the treatment of RSE. Twenty-
three studies were ultimately included in this analysis, which
included a total of 162 patients consisting of 110 adults (range 19–
88 years old) and 52 children (range 2 months–18 years old). In all
of these studies, ketamine was used to treat RSE. This study
revealed that ketamine was effective for 56.5% (59/110) of the
adults and 63.5% (33/52) of the children and that the rate of side
effects related to ketamine administration was 1.8% (2/110) in the
adults and 17.3% (9/52) in the children, supporting the use of
ketamine for the treatment of RSE in children and adults and
indicating that adverse reaction rates related to ketamine
administration were relatively small. However, this review also
has some limitations such as the retrospective heterogeneous
nature of the data, the small sample sizes of the studies included,
and the heterogeneity of the medications prior to ketamine
treatment, the timing of ketamine use, and the dosage and
duration of this drug. Thus, larger prospective studies are
necessary to assess the efﬁcacy and safety of ketamine treatment
in RSE.
4. The possible antiepileptic and neuroprotective mechanisms
of ketamine action
4.1. The possible mechanism of the effects of ketamine on SE
With decreased GABA-receptor activity, the expression of the
NMDA receptor is up-regulated, and the activity of this receptor is
also increased in late SE. The NMDA receptor is one of the main
receptor subtypes that mediates glutamatergic neurotransmission,
and it is also a nonspeciﬁc cation channel that contains the NMDA
binding site and the phencyclidine (PCP) binding site [42]. When
the cell is at rest, Mg2+, located on the inner side of the channels,
blocks the channels. When the cell membrane is depolarized, the
combined actions of glutamate and glycine on the NMDA receptor
remove the blocking effect of Mg2+, and the activation of the
receptor can induce inﬂuxes of calcium and sodium, which
participate in the transmission of excitatory nerve impulses in
different brain circuits [16]. However, ketamine, which is a
noncompetitive antagonist of the NMDA receptor, can block the
ﬂow of Ca2+ and Na+ by combining with the PCP site inside of the
ion channel of the NMDA receptor and can thereby reduce
epileptiform burst discharges and after-potentials, thus inhibiting
the conduction of excitation and playing an anticonvulsive role
[18].
4.2. The neuroprotective effects of ketamine
With prolonged SE, cell depolarization also continues, leading
to the excessive release of excitatory neurotransmitters that can
bind to a variety of receptors to produce neurotoxicity. Among
these receptors, the NMDA receptor might play a critical role in this
effect [43–47]. do Nascimento et al. [48] detected hippocampal
neuronal damage in rats in which SE had been induced by
pilocarpine. Using Fluoro-Jade (FJB) and cresyl violet staining,these authors detected multiple sites of neuronal damage 3 h, 6 h,
12 h, 24 h, 1 week, and 3 weeks after prolonged SE. These sites of
damage were primarily located in the hippocampal dentate gyrus,
the CA1 zone, and the CA3 zone. Moreover, the neuronal damage
was most extensive in the dentate hilus after 3 and 12 h of seizures
(P < 0.05). However, one week after the seizures, the greatest
neuronal damage was located in the pyramidal cell layer of the CA1
and CA3 regions in the hippocampus (P < 0.05), and the most
serious neurotoxicity was observed in the hippocampal CA1
pyramidal cell layer (P < 0.05). The NMDA receptor antagonist
ketamine not only blocks the inﬂux of Ca2+ but also exerts anti-
inﬂammatory and antioxidant effects [49,50]. Therefore, ketamine
exerts protective effects in the central nervous system. Fujikawa
[51] used pilocarpine to induce epilepsy in a rat model and then
administered 100 mg/kg ketamine or saline to the rats via
intraperitoneal injection after 10 min of seizures. Three hours
later, the seizures were terminated with intraperitoneal injections
of diazepam and phenobarbital. After 24 h, these authors
performed perfusion ﬁxation to obtain slices of the rat brains,
which were observed under a microscope. They found that, in the 5
rats that had been injected with saline, neuronal damage was
observed in 24 of 25 brain regions; however, in the 7 rats that
received ketamine treatment, the drug was found to exert
neuroprotective effects in 22 of the 24 damaged brain regions.
Regardless of whether the seizures were ultimately terminated,
this neuroprotection remained present and was beneﬁcial to the
recovery from SE.
5. Onset time
Ketamine displays relatively high fat solubility and a low
plasma protein binding rate, causing it rapidly penetrate the
blood–brain barrier; thus, ketamine exhibits the property of rapid
onset. It has been reported that, when ketamine is administered
intravenously, the interval to the maximum plasma concentration
(Tmax) is from 1 to 5 min, and when ketamine is administered
orally, the Tmax is from 15 to 30 min [52]. As observed by Kramer
[33], when a bolus of 50 mg of ketamine was intravenously
administered, followed by infusion at an initial rate of 0.6 mg/kg/h,
reduced seizure frequency, shortened seizure duration, and
decreased epileptiform discharge amplitude were immediately
observed, indicating that ketamine acts rapidly in the treatment of
RSE. This conclusion has been supported by other studies [39,53].
Additionally, Sheth and Gidal [39] noted that the onset time of
intravenous ketamine was within 90 s after initiation. However, in
the majority of cases, seizures are often completely terminated
within 24 h when ketamine is selected for the treatment of SE [25].
When ketamine is administered orally, the interval to complete
seizure control is within 24–48 h [27].
6. Dosage
Currently, the administration of ketamine for the treatment of
RSE involves intravenous and oral routes. When ketamine is
selected for RSE treatment following prolonged SE, it maybe
typically suitable after 5–6 anticonvulsants have been found to be
ineffective. This treatment choice is summarized from previous
successful reports [25,26,29], and the rationale for its use is based
on prolonged seizure duration, decreased numbers of active GABA
receptors, gradual elevation of NMDA receptor activity, and
increased numbers of NMDA receptors [14–16,54,55].
6.1. Intravenous administration
(1) Intravenous bolus followed by continuous infusion:
when ketamine is used for adult RSE, an average loading dose of
Y. Fang, X. Wang / Seizure 30 (2015) 14–20181.5 mg/kg, followed by an average infusion rate of 2.75 mg/kg/h for
4 days (0–24 days) is recommended [25]. An analysis by Gaspard
et al. [25] revealed that the maximum loading dose of ketamine is
5 mg/kg and that the maximum infusion rate is 10 mg/kg/h.
Moreover, Synowiec et al. [30] found that a bolus dose of 1–2 mg/
kg, followed by maintenance at an infusion rate of 1.3 mg/kg/h
(range 0.45–2.1 mg/kg/h) for 9.8 days (range 4–28 days), resulted
in a successful seizure control rate of 100% (11/11). When
ketamine is administered to children, we recommend a 2–3 mg/
kg bolus of ketamine every 5 min for a total of 2 administrations,
followed by maintenance at a rate of 40 mg/kg/min (range 10–
60 mg/kg/min) for 6.7 days (range 3–17 days) [26]. (2) Intravenous
infusion: Zelier et al. [31] performed continuous infusion of
ketamine at 10–40 mg/kg/min for the treatment of RSE, and the
seizures in all of the patients were ultimately effectively controlled
(2/2). In a report by Gosselin-Lefebvre et al. [56], ketamine was
initiated in 9 SE patients when 8 AEDs had failed, and the seizures
had persisted for 12 days. The average rate of ketamine infusion
was 5 mg/kg/h (range 2–15 mg/kg/h). Ultimately, the seizures
were completely halted in 4 patients (4/9), partially controlled in 3
patients (3/9), and not controlled in only 2 patients (2/9). Finally,
the recommended dosage for children is 32.5 mg/kg/min (range
10–60 mg/kg/min) when intravenous infusion of ketamine alone is
selected [57].
6.2. Oral administration
The use of oral ketamine to treat RSE has only been reported in
NCSE. The recommended dosage of ketamine is 1500–2000 mg/d
for adults [34] and 1.5 mg/kg/d, administered as two separate
doses, for children [27].
The usage of ketamine for the treatment of RSE is summarized
in Table 3.
7. Adverse reactions and precautions for ketamine use
Zeiler et al. [41] performed a systematic review, which
indicated that the adverse reactions related to ketamine treatment
for RSE were rare. However, due to the lack of controlled studies
related to this topic, concern remains warranted, primarily
regarding psychiatric symptoms during anesthesia recovery,
increased intracranial pressure (ICP), increased secretion of saliva,
increased intraocular pressure, and arrhythmia. Details regarding
the adverse reactions and precautions for ketamine use are
described as follows.
7.1. Psychiatric symptoms
The psychiatric symptoms caused by treatment of RSE with
ketamine are primarily related to hallucinations, delirium, a
ﬂoating sensation, dreams, and blurred vision [58]. The incidences
of these symptoms are 5–30%. Children are at the lowest risk forTable 3
Usage of ketamine for the treatment of RSE.
Administration Indication Contraindications [72] Dosages 
Adults 
Oral After 5–6 ADEs
failed
Allergic
Severe hypertension
1500–2000 mg/
Bolus and
infusion
After 5–6 ADEs
failed
Allergic
Severe hypertension
Bolus: 1–5 mg/k
Infusion: 0.45–1
[25,30]
Infusion After 5–6 ADEs
failed
Allergic
Severe hypertension
0.6–15 mg/kg/hpsychiatric symptoms, which are more likely to occur in patients
over 16 years old, in female patients, or when the administration
rate or dosage is too high [58]. A quiet and relaxing environment
can help to reduce the incidences of these side effects [59].
Additionally, prophylactic administration of 3.75–7.5 mg of mid-
azolam could reduce the probability and severity of adverse
reactions [59].
7.2. Increased ICP
As early as 40 years ago, there were reports that ketamine
improved the cerebral metabolic rate and increased cerebral blood
ﬂow, thereby increasing ICP [60]. However, due to the develop-
ments of related studies, researchers have proposed new
hypotheses regarding the effects of ketamine on ICP, ﬁnding that,
when patients are breathing spontaneously, ketamine causes
intracranial hypertension that is primarily associated with
increased PaCO2 in the arterial blood; however, when patients
are sedated and mechanically ventilated, the effects of ketamine on
ICP are, in fact, very small [59]. A systematic evaluation, published
in 2014, showed that, when ketamine was used for nontraumatic
neurological diseases, it did not increase ICP, and in some cases,
ketamine might even reduce ICP [61]. Gaspard et al. [25] studied 58
patients treated with ketamine and observed only 2 cases of mild
ICP elevation. Actually, prior to the initiation of ketamine, these 2
patients had suffered from brain edema secondary to anoxic brain
injury.
7.3. Increased secretion of saliva
Ketamine can induce the secretion of saliva, accompanied by
the hypersecretion of bronchial mucus, which can lead to transient
inhibition of the respiratory system or apnea. To prevent this
adverse effect, anticholinergic drugs, such as scopolamine or
atropine, can be prophylactically administered during the clinical
application of ketamine treatment [52].
7.4. Increased intraocular pressure
The effects of ketamine on intraocular pressure remain
controversial [62]. Some authors believe that ketamine can cause
an increase in intraocular pressure [63], whereas others have
stated that it can reduce intraocular pressure [64] or that ketamine
exerts no effect on intraocular pressure [65]. This discrepancy may
be attributable to the many factors that can inﬂuence intraocular
pressure, such as the aqueous humor circulation, extraocular
muscle tension, choroidal blood ﬂow, vitreous volume, etc. [50]. In
fact, the inﬂuence of ketamine on intraocular pressure has been
shown to be mild and even smaller than the effects of laryngoscopy
[50]. Thus, when ketamine is used for RSE, it exerts little effect on
intraocular pressure, and the combined use of benzodiazepines can
alleviate this effect [62].Onset time [52]
Children (0–18 y)
d [34] 1.5 mg/kg/d in two divided doses [27] 15–30 min
g
0 mg/kg/h
Bolus  2: 2–3 mg/kg
Infusion: 2.4 mg/kg/h
(range 0.6–3.6 mg/kg/h) [26]
1–5 min
 [31,56] 1.95 mg/kg/h (range 0.6–3.6 mg/kg/h) [57] 1–5 min
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The arrhythmias induced by ketamine are often tachyarrhyth-
mias, which might occur because ketamine can excite the
sympathetic nervous system and shorten atrial conduction
[66,67]. Gaspard et al. [25] examined 58 RSE patients who
received ketamine and found that only 3 patients exhibited
arrhythmias. Two of these patients exhibited supraventricular
tachycardia, and their symptoms were alleviated following the
withdrawal of ketamine. The other patient exhibited atrial
ﬁbrillation that was relieved using amiodarone.
7.6. Neurotoxicity
The effects of ketamine on the human central nervous system
remain controversial. In 1991, it was found that ketamine exerts
toxic effects on some regions of the cerebral cortex in rats.
Ketamine was found to be capable of causing regional neuronal
vacuolation or even necrosis, and since this ﬁnding, clinicians have
become more cautious regarding the selection of this drug.
However, over the last 20 years, this conclusion has yet to be
conﬁrmed or generally accepted [68]. Most researchers believe
that regular doses of ketamine cause only mild neurotoxicity,
possibly because of the short half-life of this drug in the body and
the low afﬁnity of ketamine for NMDA receptors. Moreover, this
neurotoxicity is likely limited to very young patients [69,70].
7.7. Precautions for ketamine use
Considering about the adverse reactions stated above, precau-
tions should be considered during ketamine use. Due to the
excitatory effects of ketamine on the central nervous system, the
Food and Drug Administration (FDA) recommends that ketamine
use be contraindicated in patients with severe hypertension and in
patients who are allergic to ketamine. Patients with coronary heart
disease, heart failure, glaucoma, atherosclerosis, pulmonary heart
disease, pulmonary hypertension, severe intracranial hyperten-
sion, pregnancy, a history of mental illness, hyperthyroidism,
tachyarrhythmia, adrenal pheochromocytoma, and alcoholism
should receive ketamine with caution [71]. Additionally, the
FDA has provided the following recommendations [71]: (1) slower
infusion rates and gradual increases in the dosage should be
considered because, when the ketamine administration rate or
dosage is too high, psychiatric symptoms, as well as respiratory
depression and apnea, are more likely to occur during recovery
from anesthesia; (2) to reduce seizures and ketamine-induced
respiratory depression, mechanical ventilation should be
employed prior to ketamine initiation, and vital signs, such as
breathing status and blood pressure, should be closely monitored;
(3) computed tomography should be performed to exclude the
presence of intracranial lesions that might cause intracranial
hypertension before the selection of ketamine; (4) in the elderly,
the minimum possible dose of ketamine should be selected; and
(5) ketamine might increase skeletal muscle tension in some
patients, which should be distinguished from tonic-clonic seizures.
8. Conclusions
Ketamine is a noncompetitive antagonist of glutamatergic
NMDA receptors, and its anticonvulsant effects have previously
been conﬁrmed. Recent studies have found that, during prolonged
seizures, the numbers and activities of GABA receptors gradually
decrease; thus, the commonly used ﬁrst-line and second-line AEDs
gradually fail. Simultaneously, the numbers and activities of
glutamatergic NMDA receptors increase, often causing RSE and
thus providing the possibility of the use of ketamine to treat RSE.Additionally, ketamine exerts neuroprotective effects that could
ameliorate RSE-induced neuronal damage. Therefore, in recent
years, ketamine has become increasingly used in clinical practice.
We examined many clinical studies that have investigated the
efﬁcacy of ketamine in the treatment of RSE; these studies included
multi-center, retrospective studies, prospective cohort studies and
case reports. In addition, the results of an evidence-based clinical
study, published in 2014, also suggested that ketamine might be of
potential beneﬁt, and it reported low adverse reaction rates in the
treatment of RSE in children and adults. However, to the best of our
knowledge, no controlled studies have been published that have
examined the efﬁcacy and safety of ketamine for the treatment of
RSE, constituting a limitation of our review. However, it is not
ethically permissible to establish randomized controlled trials in
patients with RSE, due to the emergent nature and high mortality
of this disease and the lack of effective drugs to treat RSE to use as a
control. In addition, the unpredictable nature, low recruitment
rates, and relatively low incidence rates of RSE have also resulted in
a lack of large-sample-size studies. In addition, the ﬁrst planned
RCT focusing on the treatment of RSE was terminated due to
insufﬁcient recruitment [72]. Thus, it will be necessary to conduct
robust prospective studies to investigate the regimens, efﬁcacy,
and safety of ketamine for the treatment of RSE.
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